scholarly journals Features of immune response in chronic exposure to industrial aerosols

2019 ◽  
Vol 95 (11) ◽  
pp. 1058-1061
Author(s):  
Elena N. Kryuchkova ◽  
L. M. Saarkoppel ◽  
I. V. Yatsyna
Keyword(s):  
Immune Response ◽  
Immune System ◽  
Humoral Immunity ◽  
Cellular Immunity ◽  
Chronic Exposure ◽  
Immune Status ◽  
Cytokine Profile ◽  
Dust Aerosols

There are considered features of disorders of the immune response in chronic exposure to dust aerosols. The detected changes of indices of the immune status of employees of the dust dangerous occupations and patients with chronic dust pathology of the lungs were unidirectional in the character, which is probably caused by manifestations of nonspecific response of the immune system to the dust factor. The deterioration of cellular immunity, humoral immunity and cytokine profile predisposes to the occurrence of immunopathologic states, contributing to the development of caused by both worksite and occupation pathology.

scholarly journals Elotuzumab Enhances the Th2-Mediated Immune Response of Dendritic Cell Induced By Immunomodulatory Drugs (IMiDs)

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 4342-4342
Author(s):  
Yoshiko Azuma ◽  
Tomoki Ito ◽  
Muneo Inaba ◽  
Kai Imai ◽  
Masaaki Hotta ◽  
...  
Keyword(s):  
Immune Response ◽  
Immune System ◽  
Dendritic Cell ◽  
Humoral Immunity ◽  
Immune Status ◽  
Fold Increase ◽  
Immune Dysfunction ◽  
Th2 Response ◽  
Humoral Immune ◽  
Before And After

Background: Elotuzumab, a humanized IgG1 monoclonal antibody targeting SLAMF7, is useful for the treatment of Relapsed or Refractory multiple myeloma (RRMM) in combination with Lenalidomide (LEN). However, cellular and molecular mechanisms underlying the immunomodulatory effects of elotuzumab still remain largely unclear. We have previously reported that LEN displays immunopotentiating activity that enhances Th2-mediated response at dendritic cell (DC) phase as upstream immune cascade associated with humoral immunity. DCs are pivotal cells in the sense of orchestrating both cell-mediated (linking with Th1) and humoral (linking with Th2) immunity as masters of the immune system. Series of analyses have clarified myeloid DCs (mDCs) play an important role in allergic immune response by the induction of Th2 response. Here, we focused on the effects of elotuzumab in combination with LEN on the function of human mDCs. Methods: Purified blood human CD11+ mDCs from healthy adult volunteers using cell sorting were cultured and analyzed by flow cytometry and ELISA. Serum were obtained from 16 MM patients with before and after elotuzumab therapy. This study was approved by the Institutional Review Board of Kansai Medical University. Results: We found that surface expression of SLAMF7 on mDCs was upregulated in response to Th2-inducing cytokine, thymic stromal lymphopoietin (TSLP) and the expression level was higher in response to TSLP than in response to toll-like receptor ligand R848. Elotuzumab at clinical in vivo plasma concentration of 30 to 300 µg/ml did not affect mDC survival and their CD86 and OX40-ligand expression when stimulated with 0.3 µM LEN and/or TSLP for 24 h. LEN enhanced TSLP-mediated Th2-recruiting chemokine CCL17/TARC from mDCs which functions as chemoattractant for memory Th2 cells and contribute to allergy and humoral immune responses, and elotuzumab significantly enhanced the LEN-mediated production of CCL17/TARC (TSLP+LEN as control vs. TSLP+LEN+100 µg/ml elotuzumab; 1.23 fold increase: p=0.003, and control vs. TSLP+LEN+300 µg/ml elotuzumab; 1.38 fold increase: p=0.038). This finding suggest elotuzumab enhances Th2-mediated immune profile at upstream phase of humoral immunity. In addition, serum CCL17 levels were analyzed in RRMM patients before and after 3 cycle elotuzumab administration (n=16). We found, serum CCL17 levels after elotuzumab administration were significantly higher compared with those before elotuzumab treatment (after; 1512 ± 459 pg/ml vs. before; 402.2 ± 87.4 pg/ml: p = 0.013). Conclusion: MM involves an element of humoral immune dysfunction. Immune status is important for the prognosis of MM, and clinical outcome can be improved by the recovery of immune status. In this context, our data showing the enhancement of Th2-mediated response by elotuzumab provide a plausible explanation for the observed clinical benefit of this antibody-drug in MM. This function of elotuzumab seems to be relevant to the treatment of MM patients under humoral immune dysfunction. Based on our data in focusing on DCs in the immune system, elotuzumab and IMiDs could function as immunostimulators of humoral immunity via mDCs, and this finding elucidated an additional cellular target of elotuzumab. Disclosures Ito: Celgene: Honoraria; Bristol-Myers Squibb: Honoraria, Research Funding.

scholarly journals ANTIGEN RECOGNITION AND THE IMMUNE RESPONSE

1972 ◽  
Vol 135 (6) ◽  
pp. 1228-1246 ◽  
Author(s):  
Sefik S. Alkan ◽  
E. Brady Williams ◽  
Danute E. Nitecki ◽  
Joel W. Goodman
Keyword(s):  
Immune Response ◽  
Humoral Immunity ◽  
Cellular Immunity ◽  
Antibody Production ◽  
Guinea Pigs ◽  
Antigen Recognition ◽  
Side Chain ◽  
Carboxyl Group ◽  
Self Help

L-Tyrosine azobenzene-p-arsonate (RAT) induced cellular immunity without antibody production in guinea pigs. Bifunctional antigens were prepared consisting of one RAT carrier moiety linked either directly to a dinitrophenyl (DNP) haptenic determinant or through one or more 6-amino-caproyl (SAC) spacers. Each SAC unit has an extended span of 8 A. Guinea pigs immunized with these conjugates developed cellular immunity directed against the RAT determinant and antibody specific for the DNP determinant. The anti-DNP response was the same with one or three SAC spacers, but was significantly weaker when the two determinants were joined without a spacer. Animals immunized with either DNP-SAC-TYR or DNP-TYR developed neither cellular nor humoral immunity. Prior immunization with RAT potentiated the secondary anti-hapten response to DNP-SAC-RAT. Modification of RAT at either the arsonate or tyrosine positions showed that other charged groups (sulfonate and trimethylammonium) could substitute for arsonate without loss of immunogenicity. Removal of either the amino or carboxyl group from the side chain of tyrosine did not abolish immunogenicity, but immunogenicity was lost upon removal of both. Immunization with symmetrical bifunctional RAT-(SAC)n-RAT and cyclo-(L-RAT-D-RAT) antigens led to cellular immunity but no anti-arsonate antibody, suggesting a barrier to "self-help." These compounds were also ineffective in inducing a secondary anti-arsonate response in animals primed with arsonate-BSA conjugates and RAT.

scholarly journals ANTIGEN RECOGNITION AND THE IMMUNE RESPONSE

1972 ◽  
Vol 136 (6) ◽  
pp. 1478-1483 ◽  
Author(s):  
Maurice E. Bush ◽  
Sefik S. Alkan ◽  
Danute E. Nitecki ◽  
Joel W. Goodman
Keyword(s):  
Bone Marrow ◽  
Immune Response ◽  
Cell Surface ◽  
Humoral Immunity ◽  
Cellular Immunity ◽  
Humoral Response ◽  
Antigen Recognition ◽  
Bifunctional Molecules ◽  
Flexible Spacer ◽  
Self Help

L-Tyrosine-p-azobenzenearsonate (RAT) induces cellular immunity without humoral antibody in guinea pigs. Asymmetric bifunctional antigens composed of one RAT moiety and one dinitrophenyl (DNP) group separated by flexible spacers induce anti-RAT cellular immunity and an anti-DNP humoral response. Symmetrical bifunctional antigens of similar design but comprised of two RAT determinants induce cellular immunity without demonstrable anti-RAT antibody. However, when the flexible spacer is replaced by a rigid decaproline chain, humoral anti-RAT responses are provoked. Since RAT contains both electropositive (azo) and electronegative (arsonate) centers, the failure of bifunctional RAT compounds with flexible spacers to induce humoral immunity might be ascribed either to intramolecular stacking, which compromises their bifunctional character, or to interaction of both determinants with receptors on the same cell surface, which would fail to satisfy the requirement for cooperation. In order to distinguish between these alternatives, symmetrical bifunctional antigens composed of two L-tyrosine-p-azophenyltrimethylammonium (TAT) determinants separated by flexible or rigid spacers were synthesized. TAT is immunogenic and does not cross-react with RAT. Furthermore, it contains only electropositive centers and consequently bifunctional molecules do not undergo intramolecular stacking. Immunization with either flexibly or rigidly spaced bifunctional TAT antigens raised anti-TAT antibody. These results conclusively demonstrate that "self-help," cooperation between bone marrow-derived and thymus-derived lymphocytes of identical or similar specificity, can occur, provided the determinants on the antigen are prevented from associating with each other.

scholarly journals СОСТОЯНИЕ ГУМОРАЛЬНОГО ИММУНИТЕТА, КАК ВАЖНЫЙ ПРОГНОСТИЧЕСКИЙ КРИТЕРИЙ ЭФФЕКТИВНОСТИ ПРОГРАММ ЭКСТРАКОРПОРАЛЬНОГО ОПЛОДОТВОРЕНИЯ ПРИ ТРУБНО-ПЕРИТОНЕАЛЬНОМ БЕСПЛОДИИ

2021 ◽  
Vol 7 (4(58)) ◽  
pp. 16-18
Author(s):  
ЮЛИЯ СЕРГЕЕВНА ЧЕХОВА ◽  
СВЕТЛАНА ВЛАДИМИРОВНА СОЛОВЬЁВА
Keyword(s):  
Immune System ◽  
Humoral Immunity ◽  
Immune Status ◽  
Reproductive Technologies ◽  
Main Group ◽  
Pregnancy Planning ◽  
Healthy Women ◽  
Preparation Stage

The indicators of humoral immunity in clinically healthy women at the stage of pregnancy planning and in patients with pipe-peritoneal infertility in the pre-infantal period of vitro incense fertilization periods are studied. The initial immune status in women of the main group did not have pathological deviations. The identified shifts in the work of the immune system in women with infertility, depending on the outcomes of the auxiliary reproductive technologies, was carried out in a multidirectional nature and could serve as a factor in a preventive forecast, in order to ensure a more differentiated approach at the preparation stage and during extracorporeal fertilization.

scholarly journals METABOLIC DETERMINANTS OF IMMUNE REACTIVITY

2017 ◽  
Vol 19 (3) ◽  
pp. 56-63
Author(s):  
Dmitry A Vologzhanin ◽  
Yuriy Sh Khalimov
Keyword(s):  
Immune Response ◽  
Immune System ◽  
Immune Status ◽  
Severe Trauma ◽  
The State ◽  
Immune Reactivity ◽  
The Moment

As a result of the study of the dynamics of nutritional and immune status in patients with severe trauma in the first 30 days of the posttraumatic period, the interrelations between the parameters of metabolism and the immune system were revealed and the predominant influence of a number of nutrients on the state of the various type of immune response was revealed. Data were obtained indicating the change in the need for immunonutrients at different times from the moment of injury. Prospective approaches to nutritional immunocorrection in patients with trauma, consisting in the differential use of separate nutrients at different period after trauma, have been identified (9 figs, bibliography: 9 refs).

scholarly journals Modern Conceptions about the Mechanisms of Interaction Between Biofilm and Cellular Immunity Factors

2020 ◽  
Vol 97 (1) ◽  
pp. 83-90
Author(s):  
N. M. Shlepotina ◽  
M. V. Peshikova ◽  
O. L. Kolesnikov ◽  
Yu. S. Shishkova
Keyword(s):  
Immune Response ◽  
Pseudomonas Aeruginosa ◽  
Immune System ◽  
Cellular Immunity ◽  
Cellular Immune Response ◽  
Growth And Development ◽  
Microbial Consortium ◽  
Significant Negative Effect ◽  
Negative Effect ◽  
Cellular Immune

Features of the cellular immune response in the presence of a microbial biofilm are well described in the literature. Based on numerous studies, it became possible to establish a number of patterns: mature biofilms are better protected from immune factors, the effectiveness of antibiofilm strategies depends on species of the microorganisms, forming the biofilm, and, accordingly, on the composition of the biopolymer matrix. For example, rhamnolipids and alginate of Pseudomonas aeruginosa exert a significant negative effect on the function of immunocompetent cells. The bacteria of biofilms became able to turn to their advantage many of the protective reactions developed by the immune system and fixed evolutionarily, applying them for the growth and development of the microbial consortium.

scholarly journals Research progress on immune response of B lymphocytes and anti-Mycobacterium tuberculosis infection

2016 ◽  
Vol 5 (1) ◽  
pp. 1-4
Author(s):  
Jiacong You
Keyword(s):  
Immune Response ◽  
Mycobacterium Tuberculosis ◽  
B Lymphocytes ◽  
Host Defense ◽  
Humoral Immunity ◽  
Cellular Immunity ◽  
Research Progress ◽  
Mycobacterium Tuberculosis Infection ◽  
Cellular Immune

Abstract Multiple studies elucidated the importance of cellular immune mechanisms for protection against Mycobacterium tuberculosis. However, recent studies showed that B lymphocytes play a role that is underestimated through various interactions with cellular immune response, forming an important aspect of host defense against M. tuberculosis bacteria. Therefore, the author hereby proposes a progressive perspective for immunology of tuberculosis, i.e., cellular immunity and humoral immunity are not necessarily mutually exclusive. The present study summarizes recent studies that support the important role of B lymphocytes in terms of M. tuberculosis infection.

Interactions between immunity and chemotherapy in the treatment of the trypanosomiases and leishmaniases

Parasitology ◽  
1992 ◽  
Vol 105 (S1) ◽  
pp. S71-S78 ◽  
Author(s):  
B. J. Berger ◽  
A. H. Fairlamb
Keyword(s):  
Immune Response ◽  
Cell Wall ◽  
Immune System ◽  
Leishmania Donovani ◽  
Immune Status ◽  
Cell Mediated Immune Response ◽  
Intact Immune System ◽  
Rapid Clearance ◽  
Increased Activity ◽  
Wall Components

SUMMARYThe immune status of a host infected withTrypanosomaspp. orLeishmaniaspp. can play an important role in successful chemotherapy. In animal models, treatment of African trypanosomiasis with difluoromethylornithine or melarsoprol requires an appropriate antibody-mediated immune response. An intact immune system is also necessary for rapid clearance of trypanosomes from the bloodstream following treatment with suramin or quinapyramine. Similarly, an efficient cell-mediated immune response is required for maximal efficacy of pentavalent antimonials in the treatment of leishmaniasis. However, the potential relationship between parasite-induced or acquired immunosuppression and effective chemotherapy has been poorly studied. Macrophages which have been activated by bacterial cell wall components or gamma-interferon are known to display increased activity againstLeishmania donovaniorTrypanosoma cruzi. In experimental and clinical visceral leishmaniasis, use of macrophage activators together with pentavalent antimonials has lowered the dose of antimony required to cure the infection.

INDUCTION OF T-CELL IMMUNE RESPONSE BY A RECOMBINANT STRAIN OF VACCINIA VIRUS EXPRESSING A CASSETTE OF STRUCTURAL PROTEIN'S GENES OF MARBURG VIRUS

2021 ◽  
Vol 1 (19) ◽  
pp. 174-176
Author(s):  
A.A. Grazhdantseva ◽  
D.V. Antonets ◽  
L.I. Karpenko ◽  
E.V. Starostina ◽  
M.B. Borgoyakova ◽  
...  
Keyword(s):  
Immune Response ◽  
T Cell ◽  
Vaccinia Virus ◽  
Humoral Immunity ◽  
Cellular Immunity ◽  
Recombinant Strain ◽  
Marburg Virus ◽  
Cell Immune Response

The constructed recombinant strain MVA-GP-VP40-MARV, in addition to the induction of humoral immunity, also forms specific cellular immunity to the Marburg virus, and therefore can be considered as a promising vaccine against Marburg fever.

scholarly journals The impact of immune disturbances on the failure of antituberculosis treatment

2016 ◽  
Vol 89 (4) ◽  
pp. 493-498 ◽  
Author(s):  
Evelina Lesnic ◽  
Serghei Ghinda ◽  
Carmen Monica Pop
Keyword(s):  
Immune Response ◽  
T Cell ◽  
Pulmonary Tuberculosis ◽  
Treatment Failure ◽  
Humoral Immunity ◽  
Cellular Immunity ◽  
Immune Complexes ◽  
Treatment Initiation ◽  
Circulating Immune Complexes ◽  
Antituberculosis Treatment

Background and aim. Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis complex, with an evolution and treatment outcome determined by the interaction between the mycobacterial and human genotypes. Various deficiencies of innate immune response starting from the first encounter of M. tuberculosis with lung cells endanger host infection control due to decreased triggering of cellular immune resistance and disturbed humoral immunity. Disturbed cell mediated immunity, known as the basic immune response in tuberculous infection, contributes to the deficient generation of central necrosis granuloma, consequently being responsible for severe clinical aspects and low final outcome. The tuberculosis patient’s immune assessment is important before treatment initiation, for establishing the risk reduction measures and increasing success rate.Material and methods. The immune study was conducted on 54 new pulmonary tuberculosis cases with treatment failure, 34 new pulmonary tuberculosis cases that successfully ended the treatment and 50 healthy group individuals. Immune assays performed were: blastic transformation of lymphocytes induced by different antigens, quantitatitve assessment of cellular immunity through CD4+ T cell and CD8+ T cell phenotyping, humoral immunity - through immunoglobulin isotyping, innate resistance – through phagocyte activity of neutrophils, the titter of anti-tuberculosis antibodies and the serum level of circulating immune complexes. Investigations were performed at the onset the treatment and at the end of intensive phase of the standard anti-tuberculosis treatment.Results. Immune disturbances evidenced in patients with treatment failure were: important deficiencies of cellular immunity, hyperactivity of humoral immunity and deficiencies of innate immunity. High predictive value for treatment failure showed the indices: deficiency of T lymphocytes count (OR=62.5) and T helper count (OR=12.5), high level of circulating immune complexes (OR=9.801), deficiency of innate resistance (decreased phagocytating index OR=2.875).Conclusions. For increasing the treatment success rate, the study of immune disturbances must be performed before of antituberculosis treatment initiation , especially of cellular immunity for the early start of immune adaptive treatment.

Sign in / Sign up

Export Citation Format

Share Document